Screening: Drug Market to Grow at 10.2% CAGR to 2022.

Drug Screening Market Report is forecast to reach $8.63 billion by 2022 from $5.32 billion in 2017 at a CAGR of 10.2% during (2017-2022) driven by growing drug and alcohol consumption; government funding in major markets, enforcement of stringent laws mandating drug and alcohol testing, and regulatory approvals and new product and service launches.

Browse 204 Market Data Tables and 42 Figures spread through 203 Pages and in-depth TOC on "Drug Screening Market by Product ((Immunoassay Analyzer, Chromatography, Breathalyzer, Rapid Test Device, Assay Kits)), Drug Screening Services, Sample Type (Urine, Hair, Oral), End User (Workplace, Criminal Justice, Hospital) - Global Forecast to 2022."

The drug screening market is highly competitive with the presence of several small and big players. Some of the players offering products for drug screening market include Alere (US), Thermo Fisher (US), Siemens Healthineers (US), Alfa Scientific Designs (US), Roche (Switzerland), MPD, Inc. (US), Shimadzu (Japan), OraSure (US), Lifeloc (US), and Drägerwerk (Germany). On the other hand, LabCorp (US), Quest Diagnostics (US), Psychemedics (US), Omega Laboratories (US), CRL (US), SureHire (Canada), and CannAmm (Canada).

In 2017, North America is expected to account for the largest share of the drug screening market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this regional segment is attributed to the growing consumption of illicit drugs, rising number of drunk-driving cases, growing awareness regarding drug screening tests and the strategic expansion of the market players in the region.

Inquire for DISCOUNT on "Drug Screening Market by Product ((Immunoassay Analyzer, Chromatography, Breathalyzer, Rapid Test Device, Assay Kits)), Drug Screening Services, Sample Type (Urine, Hair, Oral), End User (Workplace, Criminal Justice, Hospital) - Global Forecast to 2022" research report at http://www.reportsnreports.com/contacts/discount.aspx?name=345782 .

By sample type, urine samples are expected to dominate the drug screening market during the forecast period. The drug screening market is segmented into urine, breath, hair, oral, and other samples on the basis of sample type. The urine sample segment is expected to dominate the market during the forecast period due to the benefits it offers such as high accuracy in the detection of multiple drugs, cost-effectiveness, and instant results.

The Drug Screening Market is segmented into products and services. Drug screening services are expected to grow at the highest CAGR during the forecast period. The services segment is projected to register the highest CAGR during the forecast period; growth in this segment is attributed to factors such as the growing drug and alcohol consumption worldwide, funding initiatives for drug testing laboratories, new and regular service launches and regulatory approvals, and the geographic expansion of drug and alcohol testing laboratories.

The breathalyzers are expected to dominate the drug screening market in 2017. On the other hand, market growth may be limited to a certain extent due to the prohibition of workplace drug testing in some countries and the ban on alcohol consumption in several Islamic countries.

Order a copy of "Drug Screening Market by Product ((Immunoassay Analyzer, Chromatography, Breathalyzer, Rapid Test Device, Assay Kits)), Drug Screening Services, Sample Type (Urine, Hair, Oral), End User (Workplace, Criminal Justice, Hospital) - Global Forecast to 2022" research report at http://www.reportsnreports.com/purchase.aspx?name=345782 .

The report provides an overview of the drug screening market. It aims at estimating the market size and growth potential of this market across different segments such as product and service, sample type, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

The primary interviews conducted for the drug screening market report can be categorized as follows:

• By Company Type: Tier 1 - 23%; Tier 2 - 32%; Tier 3 - 45%
• By Designation: C-level - 21%; D-level - 36%; others - 43%
• By Region: North America - 42%; Europe - 37%; Asia-Pacific - 17%; RoW - 4%

Another research titled Allergy Diagnostics Market Global Forecast to 2022 says, the global allergy diagnostics market is expected to reach $5.74 billion by 2022, at a CAGR of 10.5% from 2017 to 2022.

Assay kits to register the highest CAGR during the forecast period. Diagnostic laboratories to dominate the allergy diagnostics market during the forecast period. Asia is estimated to be the fastest growing regional segment in the market during the forecast period. Companies such as Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), Danaher Corporation (US), Omega Diagnostics Group PLC (UK), Hitachi Chemical Co., Ltd. (Japan), bio Mérieux SA (France), Stallergenes Greer (UK), HOB Biotech Group Suzhou Co., Ltd. (China), HYCOR Biomedical (US), Lincoln Diagnostics, Inc. (US), EUROIMMUN AG (Germany), INDOOR Biotechnologies, Inc. (US), DR. FOOKE - Achterrath Laboratorien GmbH (Germany), R-Biopharm AG (Germany), GA Generic Assays GmbH (Germany), Tecan Trading AG (Switzerland), DST Diagnostische Systeme & Technologien GmbH (Germany), ROXALL Medical GmbH (Germany), ALK-Abelló A/S (Denmark), Angsana Molecular & Diagnostics Laboratory Pte Ltd. 

(Singapore), Allergy Therapeutics (UK), Astra Biotech GmbH (Germany), HAL Allergy Group (Netherlands), Theradiag (France), Demeditec Diagnostics GmbH (Germany) have been profiled in this 149 pages research report available at http://www.reportsnreports.com/purchase.aspx?name=320079 .

Explore more reports on Medical Devices Market at http://www.reportsnreports.com/market-research/medical-devices/ .